Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/02/2023 | 791.09% | Needham | → $9 | Reiterates | Buy → Buy |
08/28/2023 | 2078.22% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
08/02/2023 | 791.09% | Needham | $10 → $9 | Maintains | Buy |
06/26/2023 | 2078.22% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
06/15/2023 | 296.04% | B of A Securities | $1.25 → $4 | Upgrades | Underperform → Buy |
06/01/2023 | 2078.22% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
05/09/2023 | 890.1% | Needham | $12 → $10 | Maintains | Buy |
04/18/2023 | 1088.12% | Needham | → $12 | Reiterates | → Buy |
03/28/2023 | 1088.12% | Needham | → $12 | Reiterates | → Buy |
03/20/2023 | 197.03% | Morgan Stanley | $9 → $3 | Maintains | Equal-Weight |
03/16/2023 | 48.51% | B of A Securities | $8 → $1.5 | Downgrades | Neutral → Underperform |
03/16/2023 | 1088.12% | Needham | $16 → $12 | Maintains | Buy |
03/16/2023 | 2078.22% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
03/07/2023 | 593.07% | Credit Suisse | $6.5 → $7 | Upgrades | Underperform → Neutral |
03/06/2023 | 1385.15% | JMP Securities | → $15 | Reiterates | → Market Outperform |
03/06/2023 | 1484.16% | Needham | $12 → $16 | Maintains | Buy |
03/06/2023 | 2078.22% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
02/27/2023 | 791.09% | JP Morgan | $8 → $9 | Maintains | Neutral |
02/27/2023 | 692.08% | B of A Securities | → $8 | Reinstates | → Neutral |
02/22/2023 | 1088.12% | Needham | → $12 | Reiterates | → Buy |
02/03/2023 | 791.09% | Morgan Stanley | → $9 | Upgrades | Underweight → Equal-Weight |
11/02/2022 | 791.09% | Morgan Stanley | $7 → $9 | Maintains | Underweight |
08/03/2022 | 494.06% | Credit Suisse | $7 → $6 | Downgrades | Neutral → Underperform |
07/15/2022 | 593.07% | Morgan Stanley | $5 → $7 | Maintains | Underweight |
05/24/2022 | 197.03% | Goldman Sachs | $3.5 → $3 | Maintains | Sell |
05/05/2022 | — | JP Morgan | Upgrades | Underweight → Neutral | |
03/10/2022 | 2078.22% | HC Wainwright & Co. | → $22 | Initiates Coverage On | → Buy |
01/14/2022 | 494.06% | Credit Suisse | $8 → $6 | Maintains | Neutral |
12/09/2021 | 1088.12% | Needham | $20 → $12 | Maintains | Buy |
12/06/2021 | 395.05% | Goldman Sachs | $8 → $5 | Maintains | Sell |
12/06/2021 | 692.08% | Credit Suisse | $11 → $8 | Maintains | Neutral |
10/19/2021 | 989.11% | Credit Suisse | $28 → $11 | Downgrades | Outperform → Neutral |
10/14/2021 | 989.11% | Morgan Stanley | → $11 | Downgrades | Equal-Weight → Underweight |
08/04/2021 | 1583.17% | Morgan Stanley | $22 → $17 | Maintains | Equal-Weight |
08/03/2021 | 11187.13% | Needham | $134 → $114 | Maintains | Strong Buy |
05/05/2021 | 3464.36% | Credit Suisse | $45 → $36 | Maintains | Outperform |
05/05/2021 | 2276.24% | Northland Capital Markets | $30 → $24 | Maintains | Market Perform |
05/05/2021 | 2078.22% | Morgan Stanley | $30 → $22 | Maintains | Equal-Weight |
05/05/2021 | 10890.1% | JMP Securities | $191 → $111 | Maintains | Market Outperform |
05/05/2021 | 1880.2% | Stifel | $37 → $20 | Downgrades | Buy → Hold |
03/11/2021 | 2870.3% | Morgan Stanley | → $30 | Initiates Coverage On | → Equal-Weight |
02/24/2021 | 13167.33% | Needham | $150 → $134 | Maintains | Strong Buy |
02/12/2021 | 2870.3% | Jefferies | $40 → $30 | Downgrades | Buy → Hold |
02/09/2021 | 2276.24% | Goldman Sachs | → $24 | Downgrades | Neutral → Sell |
01/15/2021 | 3365.35% | B of A Securities | → $35 | Downgrades | Buy → Neutral |
11/10/2020 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
10/15/2020 | 5048.51% | B of A Securities | $55 → $52 | Maintains | Buy |
08/17/2020 | 5345.54% | B of A Securities | $60 → $55 | Maintains | Buy |
08/11/2020 | 4355.45% | Credit Suisse | $83 → $45 | Downgrades | Outperform → Neutral |
05/07/2020 | 6830.69% | Jefferies | $85 → $70 | Maintains | Buy |
04/16/2020 | 4058.42% | Northland Capital Markets | $60 → $42 | Maintains | Market Perform |
04/01/2020 | 4850.5% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
03/17/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
02/28/2020 | 4553.47% | JP Morgan | $46 → $47 | Maintains | Neutral |
02/24/2020 | 15543.56% | Needham | $144 → $158 | Maintains | Strong Buy |
02/24/2020 | — | Northland Capital Markets | Downgrades | Outperform → Market Perform | |
02/14/2020 | 8018.81% | Citigroup | $73 → $82 | Downgrades | Buy → Neutral |
09/18/2019 | 6830.69% | Stifel | $112 → $70 | Maintains | Buy |
09/16/2019 | 4355.45% | Goldman Sachs | $55 → $45 | Upgrades | Sell → Neutral |
05/29/2019 | 4850.5% | Goldman Sachs | → $50 | Downgrades | Neutral → Sell |
04/26/2019 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
03/13/2019 | 4553.47% | JP Morgan | $38 → $47 | Upgrades | Underweight → Neutral |
12/13/2018 | 4355.45% | Goldman Sachs | → $45 | Initiates Coverage On | → Sell |
10/16/2018 | 8018.81% | BTIG | → $82 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
10/02/2023 | 791.09% | 李约瑟 | →$9 | 重申 | 购买→购买 |
2023年08月28日 | 2078.22% | HC Wainwright公司 | →$22 | 重申 | 购买→购买 |
08/02/2023 | 791.09% | 李约瑟 | $10→$9 | 维护 | 买 |
2023/06/26 | 2078.22% | HC Wainwright公司 | →$22 | 重申 | 购买→购买 |
2023/06/15 | 296.04% | B of A证券 | $1.25→$4 | 升级 | 表现不佳的→收购 |
06/01/2023 | 2078.22% | HC Wainwright公司 | →$22 | 重申 | →购买 |
05/09/2023 | 890.1% | 李约瑟 | $12→$10 | 维护 | 买 |
04/18/2023 | 1088.12% | 李约瑟 | →$12 | 重申 | →购买 |
03/28/2023 | 1088.12% | 李约瑟 | →$12 | 重申 | →购买 |
03/20/2023 | 197.03% | 摩根士丹利 | $9→$3 | 维护 | 等重 |
03/16/2023 | 48.51% | B of A证券 | $8→$1.5 | 评级下调 | 中性→表现不佳 |
03/16/2023 | 1088.12% | 李约瑟 | $16→$12 | 维护 | 买 |
03/16/2023 | 2078.22% | HC Wainwright公司 | →$22 | 重申 | →购买 |
03/07/2023 | 593.07% | 瑞士信贷 | $6.5→$7 | 升级 | 表现不佳的→中性 |
03/06/2023 | 1385.15% | JMP证券 | →$15 | 重申 | →市场跑赢大盘 |
03/06/2023 | 1484.16% | 李约瑟 | $12→$16 | 维护 | 买 |
03/06/2023 | 2078.22% | HC Wainwright公司 | →$22 | 重申 | →购买 |
02/27/2023 | 791.09% | 摩根大通 | $8→$9 | 维护 | 中性 |
02/27/2023 | 692.08% | B of A证券 | →$8 | 恢复 | →中性 |
02/22/2023 | 1088.12% | 李约瑟 | →$12 | 重申 | →购买 |
02/03/2023 | 791.09% | 摩根士丹利 | →$9 | 升级 | 重量不足的→等重 |
11/02/2022 | 791.09% | 摩根士丹利 | $7→$9 | 维护 | 体重不足 |
08/03/2022 | 494.06% | 瑞士信贷 | $7→$6 | 评级下调 | 中性→表现不佳 |
07/15/2022 | 593.07% | 摩根士丹利 | $5→$7 | 维护 | 体重不足 |
2022年05月24日 | 197.03% | 高盛 | $3.5→$3 | 维护 | 卖 |
05/05/2022 | - | 摩根大通 | 升级 | 减重→中性 | |
03/10/2022 | 2078.22% | HC Wainwright公司 | →$22 | 开始承保 | →购买 |
2022年01月14日 | 494.06% | 瑞士信贷 | $8→$6 | 维护 | 中性 |
12/09/2021 | 1088.12% | 李约瑟 | $20→$12 | 维护 | 买 |
12/06/2021 | 395.05% | 高盛 | $8→$5 | 维护 | 卖 |
12/06/2021 | 692.08% | 瑞士信贷 | $11→$8 | 维护 | 中性 |
10/19/2021 | 989.11% | 瑞士信贷 | $28→$11 | 评级下调 | 跑赢→中性 |
10/14/2021 | 989.11% | 摩根士丹利 | →$11 | 评级下调 | 等重→减码 |
08/04/2021 | 1583.17% | 摩根士丹利 | $22→$17 | 维护 | 等重 |
08/03/2021 | 11187.13% | 李约瑟 | $134→$114 | 维护 | 强势购买 |
05/05/2021 | 3464.36% | 瑞士信贷 | $45→$36 | 维护 | 跑赢大盘 |
05/05/2021 | 2276.24% | 北国资本市场 | $30→$24 | 维护 | 市场表现 |
05/05/2021 | 2078.22% | 摩根士丹利 | $30→$22 | 维护 | 等重 |
05/05/2021 | 10890.1% | JMP证券 | $191→$111 | 维护 | 市场表现强于大盘 |
05/05/2021 | 1880.2% | Stifel | $37→$20 | 评级下调 | 购买→Hold |
03/11/2021 | 2870.3% | 摩根士丹利 | →$30 | 开始承保 | →等重 |
02/24/2021 | 13167.33% | 李约瑟 | $150→$134 | 维护 | 强势购买 |
02/12/2021 | 2870.3% | 杰富瑞 | $40→$30 | 评级下调 | 购买→Hold |
02/09/2021 | 2276.24% | 高盛 | →$24 | 评级下调 | 中性→销售 |
2021/01/15 | 3365.35% | B of A证券 | →$35 | 评级下调 | 购买→中性 |
11/10/2020 | - | 瑞士信贷 | 升级 | 中性→表现优异 | |
10/15/2020 | 5048.51% | B of A证券 | $55→$52 | 维护 | 买 |
2020/08/17 | 5345.54% | B of A证券 | $60→$55 | 维护 | 买 |
2020年08月11日 | 4355.45% | 瑞士信贷 | $83→$45 | 评级下调 | 跑赢→中性 |
05/07/2020 | 6830.69% | 杰富瑞 | $85→$70 | 维护 | 买 |
04/16/2020 | 4058.42% | 北国资本市场 | $60→$42 | 维护 | 市场表现 |
04/01/2020 | 4850.5% | B of A证券 | →$50 | 开始承保 | →购买 |
03/17/2020 | - | 花旗集团 | 升级 | 中性→购买 | |
02/28/2020 | 4553.47% | 摩根大通 | $46→$47 | 维护 | 中性 |
02/24/2020 | 15543.56% | 李约瑟 | $144→$158 | 维护 | 强势购买 |
02/24/2020 | - | 北国资本市场 | 评级下调 | 跑赢→市场表现 | |
02/14/2020 | 8018.81% | 花旗集团 | $73→$82 | 评级下调 | 购买→中性 |
2019年09月18日 | 6830.69% | Stifel | $112→$70 | 维护 | 买 |
2019/09/16 | 4355.45% | 高盛 | $55→$45 | 升级 | 卖出→中性 |
2019年05月29日 | 4850.5% | 高盛 | →$50 | 评级下调 | 中性→销售 |
2019年04月26日 | - | 高盛 | 升级 | 卖出→中性 | |
2019/03/13 | 4553.47% | 摩根大通 | $38→$47 | 升级 | 减重→中性 |
2018年12月13日 | 4355.45% | 高盛 | →$45 | 开始承保 | →销售 |
2018年10月16日 | 8018.81% | BTIG | →$82 | 开始承保 | →购买 |
What is the target price for Esperion Therapeutics (ESPR)?
Esperion Treateutics(ESPR)的目标价格是多少?
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Needham on October 2, 2023. The analyst firm set a price target for $9.00 expecting ESPR to rise to within 12 months (a possible 791.09% upside). 22 analyst firms have reported ratings in the last year.
Needham于2023年10月2日报道了Esperion治疗公司(纳斯达克:ESPR)的最新目标价。这家分析公司将目标价定为9美元,预计每股收益将在12个月内升至(可能上涨791.09%)。过去一年,有22家分析公司公布了评级。
What is the most recent analyst rating for Esperion Therapeutics (ESPR)?
Esperion Treateutics(ESPR)的最新分析师评级是什么?
The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Needham, and Esperion Therapeutics reiterated their buy rating.
Needham提供了对Esperion Treateutics(纳斯达克代码:ESPR)的最新分析师评级,Esperion Treateutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?
Esperion Treeutics(ESPR)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析师在进行了广泛的研究后得出股票评级,其中包括查阅公共财务报表,与Esperion Treeutics的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。Esperion治疗公司的上一次评级是在2023年10月2日提交的,所以你应该预计下一次评级将在2024年10月2日左右的某个时候提供。
Is the Analyst Rating Esperion Therapeutics (ESPR) correct?
分析师对Esperion Treeutics(ESPR)的评级正确吗?
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $9.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.01, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的Esperion治疗(ESPR)评级被重申,目标价在0.00美元至9.00美元之间。Esperion Treateutics(ESPR)目前的交易价格为1.01美元,在分析师的预测范围内。